혈류감염 검사 시장 : 제품별, 샘플 유형별, 기술별, 최종 용도별, 예측(2024-2032년)

Bloodstream Infection Testing Market size will grow at 4.9% CAGR from 2024 to 2032, propelled by advancements in diagnostic technologies and instruments like mass spectrometry and automated blood culture systems. Rising innovations are offering faster, more accurate, and efficient testing methods for improving patient outcomes. Additionally, collaborations between healthcare companies for the development of novel testing solutions will contribute to the market expansion. The synergy between advanced technologies and collaborative efforts in the healthcare sector will also help meet the rising demand for precise and timely diagnosis of bloodstream infections.

For instance, in November 2023, Oxford Nanopore and Day Zero Diagnostics (DZD) collaborated to create a comprehensive solution for diagnosing bloodstream infections, a primary contributor to sepsis, a life-threatening condition. This partnership also offered an end-to-end diagnostic solution for enhanced patient outcomes.

The bloodstream infection testing industry is classified into sample type, technology, end-use, and region.

Based on product, the market share from the instruments segment will garner 4.5% CAGR up to 2032. This is due to the increasing adoption of automated instruments for faster and accurate detection of bloodstream infections. Instruments, such as blood culture systems and molecular diagnostic platforms, offer rapid results and improve patient outcomes. Lately, there have been rising advancements in instrument technology, such as enhanced sensitivity and specificity. The growing emphasis on early and precise diagnosis will also add to the demand for instruments.

Bloodstream infection testing industry from the mass spectroscopy technology segment will witness a substantial upswing at 4.9% CAGR through 2032. The growth is driven by the accuracy and efficiency of mass spectrometry in identifying pathogens and determining antibiotic resistance. Mass spectrometry enables rapid and comprehensive analysis of microbial proteins for aiding in timely and targeted treatment decisions. With the growing demand for precise and reliable infection testing methods, the deployment of mass spectroscopy is rising. Moreover, increasing adoption in clinical laboratories and hospitals will further propel the segment growth.

Asia Pacific bloodstream infection testing industry share will register a 5.2% CAGR from 2024 to 2032, owing to the increasing burden of infectious diseases, rising awareness about the importance of early detection, and improving healthcare infrastructure. With the large population in countries like China, India, and Japan, there is a growing focus on healthcare advancements. Additionally, the rising demand for innovative diagnostic technologies will further strengthen Asia Pacific's position as a key contributor in the bloodstream infection testing market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of infectious diseases
    • 3.2.1.2 Technological advancements in bloodstream infection testing
    • 3.2.1.3 Development and adoption of point-of-care testing (POCT) devices
    • 3.2.1.4 Increased awareness and focus on healthcare-associated infections (HAIs)
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limitations of the existing tests
    • 3.2.2.2 High initial setup and ongoing maintenance costs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Competitive analysis of major market players
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Reagents & consumables
• 5.3 Instruments

Chapter 6 Market Estimates and Forecast, By Sample Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Whole blood
• 6.3 Blood culture

Chapter 7 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 PCR
• 7.3 Mass spectroscopy
• 7.4 In situ hybridization
• 7.5 Other technologies

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals & diagnostic centers
• 8.3 Academic & research institutes
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Becton, Dickinson and Company
• 10.3 Bio-Rad Laboratories, Inc.
• 10.4 bioMérieux SA
• 10.5 Bruker Corporation
• 10.6 Danaher Corporation
• 10.7 F. Hoffmann-La Roche Ltd.
• 10.8 Luminex Corporation
• 10.9 Siemens Healthineers AG
• 10.10 Thermo Fisher Scientific Inc.